Screening for abnormal blood glucose and type 2 diabetes mellitus: U.S. preventive services task force recommendation statement

Annals of Internal Medicine

Volumn 163, Issue 11, 2015, Pages 861-868

  Siu, Albert L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; GLUCOSE; HEMOGLOBIN A1C; METFORMIN;

ASYMPTOMATIC DISEASE; BEHAVIOR THERAPY; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); DIET; EARLY DIAGNOSIS; GLUCOSE BLOOD LEVEL; HEALTH PROMOTION; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; META ANALYSIS (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT COUNSELING; PATIENT REFERRAL; PHYSICAL ACTIVITY; PREVENTIVE HEALTH SERVICE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STANDARD; SYSTEMATIC REVIEW; UNITED STATES; ADULT; AGED; CARDIOVASCULAR DISEASES; COMPLICATION; COST OF ILLNESS; DIABETES MELLITUS, TYPE 2; GLUCOSE METABOLISM DISORDERS; MASS SCREENING; MIDDLE AGED; PRACTICE GUIDELINE; RISK ASSESSMENT;

ADULT; AGED; ASYMPTOMATIC DISEASES; CARDIOVASCULAR DISEASES; COST OF ILLNESS; DIABETES MELLITUS, TYPE 2; GLUCOSE METABOLISM DISORDERS; HUMANS; MASS SCREENING; MIDDLE AGED; RISK ASSESSMENT;

EID: 84948692247     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M15-2345     Document Type: Review

References (51)

1. Division of Diabetes Translation, National Center for Chronic Disease Prevention and Health Promotion. National Diabetes Statistics Report, 2014. Atlanta: Centers for Disease Control and Prevention; 2014. Accessed at www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf on 18 September 2015.
2. Selph S, Dana T, Blazina I, Bougatsos C, Patel H, Chou R. Screening for Type 2 Diabetes Mellitus: Systematic Review to Update the 2008 U.S. Preventive Services Task Force Recommendation. Evidence synthesis no. 117. AHRQ publication no. 13-05190-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2014.
3. Takahashi O, Farmer AJ, Shimbo T, Fukui T, Glasziou PP. A1C to detect diabetes in healthy adults: when should we recheck? Diabetes Care. 2010;33:2016-7. [PMID: 20566678]
4. Kahn R, Alperin P, Eddy D, Borch-Johnsen K, Buse J, Feigelman J, et al. Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. Lancet. 2010;375:1365-74. [PMID: 20356621]
5. Mortaz S, Wessman C, Duncan R, Gray R, Badawi A. Impact of screening and early detection of impaired fasting glucose tolerance and type 2 diabetes in Canada: a Markov model simulation. Clinicoecon Outcomes Res. 2012;4:91-7. [PMID: 22553425]
6. Waugh N, Scotland G, McNamee P, Gillett M, Brennan A, Goyder E, et al. Screening for type 2 diabetes: literature review and economic modelling. Health Technol Assess. 2007;11:iii-iv, ix-xi, 1-125. [PMID: 17462167]
7. Herman WH, Ye W, Griffin SJ, Simmons RK, Davies MJ, Khunti K, et al. Early detection and treatment of type 2 diabetes reduce cardiovascular morbidity and mortality: a simulation of the results of the Anglo-Danish-Dutch Study of Intensive Treatment in People With Screen-Detected Diabetes in Primary Care (ADDITION-Europe). Diabetes Care. 2015;38:1449-55. [PMID: 25986661]
8. Simmons RK, Echouffo-Tcheugui JB, Sharp SJ, Sargeant LA, Williams KM, Prevost AT, et al. Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a clusterrandomised controlled trial. Lancet. 2012;380:1741-8. [PMID: 23040422]
9. Simmons RK, Rahman M, Jakes RW, Yuyun MF, Niggebrugge AR, Hennings SH, et al. Effect of population screening for type 2 diabetes on mortality: long-Term follow-up of the Ely cohort. Diabetologia. 2011;54:312-9. [PMID: 20978739]
10. Selph S, Dana T, Blazina I, Bougatsos C, Patel H, Chou R. Screening for type 2 diabetes mellitus: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2015;162:765-76. [PMID: 25867111]
11. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403. [PMID: 11832527]
12. Uusitupa M, Peltonen M, LindstromJ, Aunola S, Ilanne-Parikka P, Keina nen-Kiukaanniemi S, et al; Finnish Diabetes Prevention Study Group. Ten-year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study-secondary analysis of the randomized trial. PLoS One. 2009;4:e5656. [PMID: 19479072]
13. Li G, Zhang P, Wang J, Gregg EW, Yang W, Gong Q, et al. The long-Term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet. 2008;371:1783-9. [PMID: 18502303]
14. Li G, Zhang P, Wang J, An Y, Gong Q, Gregg EW, et al. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study. Lancet Diabetes Endocrinol. 2014;2:474-80. [PMID: 24731674]
15. Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal TP, Hemmingsen C, et al. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2013;11:CD008143. [PMID: 24214280]
16. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassai B, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-Analysis of randomised controlled trials. BMJ. 2011;343:d4169. [PMID: 21791495]
17. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317:703-13. [PMID: 9732337]
18. Hansson L, Zanchetti A, Carruthers SG, Dahlo f B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and lowdose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:1755-62. [PMID: 9635947]
19. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med. 1998;338:645-52. [PMID: 9486993]
20. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int. 2002;61:1086-97. [PMID: 11849464]
21. Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, et al; ACCORD Study Group. Effects of intensive bloodpressure control in type 2 diabetes mellitus. N Engl J Med. 2010; 362:1575-85. [PMID: 20228401]
22. Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, et al; ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370:829-40. [PMID: 17765963]
23. Reboldi G, Gentile G, Angeli F, Ambrosio G, Mancia G, Verdecchia P. Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-Analysis in 73,913 patients. J Hypertens. 2011;29:1253-69. [PMID: 21505352]
24. Bangalore S, Kumar S, Lobach I, Messerli FH. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-Analyses of randomized trials. Circulation. 2011;123:2799-810, 9 p following 810. [PMID: 21632497]
25. Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, et al; ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563-74. [PMID: 20228404]
26. Tajima N, Kurata H, Nakaya N, Mizuno K, Ohashi Y, Kushiro T, et al; Primary Prevention Group of Adult Japanese (MEGA) Study. Pravastatin reduces the risk for cardiovascular disease in Japanese hypercholesterolemic patients with impaired fasting glucose or diabetes: diabetes subanalysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study. Atherosclerosis. 2008;199:455-62. [PMID: 18635188]
27. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, et al; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-Analysis. Lancet. 2008;371:117-25. [PMID: 18191683]
28. Griffin SJ, Borch-Johnsen K, Davies MJ, Khunti K, Rutten GE, Sandb A, et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet. 2011;378:156-67. [PMID: 21705063]
29. Simmons RK, Sharp SJ, Sandb A, Borch-Johnsen K, Davies MJ, Khunti K, et al. Does early intensive multifactorial treatment reduce total cardiovascular burden in individuals with screen-detected diabetes? Findings from the ADDITION-Europe cluster-randomized trial. Diabet Med. 2012;29:e409-16. [PMID: 22823477]
30. Zoungas S, de Galan BE, Ninomiya T, Grobbee D, Hamet P, Heller S, et al; ADVANCE Collaborative Group. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial. Diabetes Care. 2009; 32:2068-74. [PMID: 19651921]
31. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580-91. [PMID: 18256393]
32. Howard BV, Roman MJ, Devereux RB, Fleg JL, Galloway JM, Henderson JA, et al. Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. JAMA. 2008;299:1678-89. [PMID: 18398080]
33. Araki A, Iimuro S, Sakurai T, Umegaki H, Iijima K, Nakano H, et al; Japanese Elderly Diabetes Intervention Trial Study Group. Longterm multiple risk factor interventions in Japanese elderly diabetic patients: the Japanese Elderly Diabetes Intervention Trial-study design, baseline characteristics and effects of intervention. Geriatr Gerontol Int. 2012;12 Suppl 1:7-17. [PMID: 22435936]
34. De Berardis G, Sacco M, Strippoli GF, Pellegrini F, Graziano G, Tognoni G, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-Analysis of randomised controlled trials. BMJ. 2009;339:b4531. [PMID: 19897665]
35. Stavrakis S, Stoner JA, Azar M, Wayangankar S, Thadani U. Lowdose aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-Analysis. Am J Med Sci. 2011;341:1-9. [PMID: 21191260]
36. Park P, Simmons RK, Prevost AT, Griffin SJ. Screening for type 2 diabetes is feasible, acceptable, but associated with increased shortterm anxiety: a randomised controlled trial in British general practice. BMC Public Health. 2008;8:350. [PMID: 18840266]
37. Rahman M, Simmons RK, Hennings SH, Wareham NJ, Griffin SJ. Effect of screening for Type 2 diabetes on population-level self-rated health outcomes and measures of cardiovascular risk: 13-year follow-up of the Ely cohort. Diabet Med. 2012;29:886-92. [PMID: 22283392]
38. Paddison CA, Eborall HC, French DP, Kinmonth AL, Prevost AT, Griffin SJ, et al. Predictors of anxiety and depression among people attending diabetes screening: a prospective cohort study embedded in the ADDITION (Cambridge) randomized control trial. Br J Health Psychol. 2011;16:213-26. [PMID: 21226792]
39. Davies MJ, Heller S, Skinner TC, Campbell MJ, Carey ME, Cradock S, et al; Diabetes Education and Self Management for Ongoing and Newly Diagnosed Collaborative. Effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial. BMJ. 2008;336:491-5. [PMID: 18276664]
40. Saito T, Watanabe M, Nishida J, Izumi T, Omura M, Takagi T, et al; Zensharen Study for Prevention of Lifestyle Diseases Group. Lifestyle modification and prevention of type 2 diabetes in overweight Japanese with impaired fasting glucose levels: a randomized controlled trial. Arch Intern Med. 2011;171:1352-60. [PMID: 21824948]
41. Diabetes Prevention Program Research Group. Long-Term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care. 2012;35:731-7. [PMID: 22442396]
42. Nijpels G, Boorsma W, Dekker JM, Kostense PJ, Bouter LM, Heine RJ. A study of the effects of acarbose on glucose metabolism in patients predisposed to developing diabetes: the Dutch acarbose intervention study in persons with impaired glucose tolerance (DAISI). Diabetes Metab Res Rev. 2008;24:611-6. [PMID: 18756586]
43. Holman RR, Haffner SM, McMurray JJ, Bethel MA, Holzhauer B, Hua TA, et al; NAVIGATOR Study Group. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010;362:1463-76. [PMID: 20228402]
44. McMurray JJ, Holman RR, Haffner SM, Bethel MA, Holzhauer B, Hua TA, et al; NAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010;362:1477-90. [PMID: 20228403]
45. Dagenais GR, Gerstein HC, Holman R, Budaj A, Escalante A, Hedner T, et al; DREAM Trial Investigators. Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. Diabetes Care. 2008;31:1007-14. [PMID: 18268075]
46. American Diabetes Association. Standards of medical care in diabetes-2015. Diabetes Care. 2015; 38 Suppl 1:S1-S90.
47. Handelsman Y, Mechanick JI, Blonde L, Grunberger G, Bloomgarden ZT, Bray GA, et al; AACE Task Force for Developing Diabetes Comprehensive Care Plan. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract. 2011;17 Suppl 2:1-53. [PMID: 21474420]
48. American Academy of Family Physicians. Clinical preventive service recommendation: diabetes. Leawood, KS: American Academy of Family Physicians; 2008. Accessed at www.aafp.org/patient-care/clinical-recommendations/all/diabetes.html on 18 September 2015.
49. Colagiuri S, Davies D, Girgis S, Colagiuri R. National evidence based guideline for case detection and diagnosis of type 2 diabetes. Canberra, Australia: National Health and Medical Research Council; 2009. Accessed at www.nhmrc.gov.au/-files-nhmrc/file/publications/synopses/di17-diabetes-detection-diagnosis.pdf on 18 September 2015.
50. Diabetes UK. Early identification of people with type 2 diabetes (Sep 2014). London: Diabetes UK; 2014. Accessed at www .diabetes.org.uk/About-us/What-we-say/Diagnosis-prevention/Early -identification-of-people-with-Type-2-diabetes on 18 September 2015.
51. Pottie K, Jaramillo A, Lewin G, Dickinson J, Bell N, Brauer P, et al; Canadian Task Force on Preventive Health Care. Recommendations on screening for type 2 diabetes in adults. CMAJ. 2012;184:1687-96. [PMID: 23073674] doi:10.1503/cmaj.120732